A phase II study of pembrolizumab and eribulin in patients with HR-positive/HER2-negative metastatic breast cancer previously treated with anthracyclines and taxanes (KELLY study) / J. Manuel Pérez-García, A.L.. - In: CANCER RESEARCH. - ISSN 0008-5472. - 78:13_suppl.(2018), pp. CT152.1-CT152.1. (AACR Annual Meeting 2018) [10.1158/1538-7445.AM2018-CT152].
A phase II study of pembrolizumab and eribulin in patients with HR-positive/HER2-negative metastatic breast cancer previously treated with anthracyclines and taxanes (KELLY study)
G. Curigliano;
2018
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Abstract-CT152.pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Licenza:
Nessuna licenza
Dimensione
80.41 kB
Formato
Adobe PDF
|
80.41 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
